联邦制药(03933.HK)预期中期净溢利约18.5亿元

Core Viewpoint - The company expects a net profit of approximately RMB 1,850,000,000 for the six months ending June 30, 2025, an increase from RMB 1,491,000,000 in the same period last year, primarily driven by licensing fee income from Novo Nordisk A/S [1] Financial Performance - The increase in net profit is mainly attributed to licensing fee income of approximately RMB 1,100,000,000 from Novo Nordisk A/S [1] - However, there was a decline in segment profits for intermediates by approximately RMB 430,000,000 and for active pharmaceutical ingredients by approximately RMB 270,000,000, which partially offset the overall profit increase [1]